Zacks: Brokerages Anticipate Syros Pharmaceuticals (SYRS) Will Announce Quarterly Sales of $1.33 Million

Share on StockTwits

Equities research analysts forecast that Syros Pharmaceuticals (NASDAQ:SYRS) will post $1.33 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Syros Pharmaceuticals’ earnings. The highest sales estimate is $3.21 million and the lowest is $370,000.00. The company is scheduled to issue its next quarterly earnings results on Wednesday, August 8th.

On average, analysts expect that Syros Pharmaceuticals will report full-year sales of $3.34 million for the current year, with estimates ranging from $370,000.00 to $10.00 million. For the next year, analysts expect that the company will post sales of $1.53 million per share, with estimates ranging from $600,000.00 to $2.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, May 10th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.14). The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $3.41 million.

A number of analysts recently commented on SYRS shares. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 22nd. Zacks Investment Research cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 16th. Wedbush reiterated an “outperform” rating and set a $13.00 price objective (up previously from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. Finally, Cann restated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, May 10th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.13.

Syros Pharmaceuticals traded down $2.25, reaching $10.53, during midday trading on Friday, MarketBeat Ratings reports. 485,500 shares of the company were exchanged, compared to its average volume of 220,199. The stock has a market cap of $424.49 million, a PE ratio of -4.94 and a beta of -2.69. Syros Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $24.38.

A number of institutional investors and hedge funds have recently bought and sold shares of SYRS. Redmile Group LLC grew its holdings in Syros Pharmaceuticals by 159.3% in the 1st quarter. Redmile Group LLC now owns 1,652,240 shares of the company’s stock valued at $21,446,000 after buying an additional 1,015,008 shares during the period. ARK Investment Management LLC grew its holdings in Syros Pharmaceuticals by 519.7% in the 4th quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock valued at $8,122,000 after buying an additional 700,058 shares during the period. BlackRock Inc. grew its holdings in Syros Pharmaceuticals by 61.7% in the 1st quarter. BlackRock Inc. now owns 929,537 shares of the company’s stock valued at $12,066,000 after buying an additional 354,591 shares during the period. Millennium Management LLC purchased a new stake in Syros Pharmaceuticals in the 1st quarter valued at about $2,126,000. Finally, GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals in the 1st quarter valued at about $1,414,000. Institutional investors own 56.84% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply